

**RECOMMENDED NON-TEXTBOOK REGULATORY READINGS
FOR PREPARATION OF THE
AMERICAN COLLEGE OF VETERINARY CLINICAL PHARMACOLOGY EXAM**

Regulatory Related Topics

FDA Regulation of Animal Drugs [LINK](#)

FDA Resources for Veterinarians [LINK](#)

A. Guidance for Industry (GFI)

Although links are provided below, these often change and it is the responsibility of the examinee to search and find the documents.

The general guidance search tool [LINK](#)

The specific guidance by number [LINK](#)

The CVM GFI website [LINK](#)

Both CVM and CDER GFIs may be used for veterinary drug approval, particularly for bioanalytical method validation, dissolution studies, and manufacturing. These are referred to as “Cross-cutting” guidelines. [LINK](#)

As of December 2020, there are several GFIs that are currently under revision or development [LINK](#)

VICH GL24 - Management of Adverse Event Reports (AER's) [LINK](#)

Antimicrobial Resistance

GFI # 152- Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern [LINK](#)

GFI # 209 - The Judicious Use of Medically Important Antimicrobial Drugs in Food- Producing Animals [LINK](#)

Additional non-guidance document: FDA’s Strategy on Antimicrobial Resistance – Questions and Answers [LINK](#)

CVM’s Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings [LINK](#)

Chemistry Manufacturing and Controls (CMC) Bioanalytical Method Validation

The most recent (May 2018) CDER and CVM bioanalytical method validation GFI is the one that CVM uses to evaluate methods. [LINK](#)

Generics

GFI #35 Bioequivalence Guidance [LINK](#)

GFI #224 (VICH GL52) Bioequivalence : Blood level Bioequivalence Study [LINK](#)

The statistical supplement to GFI #224 [LINK](#)

GFI #171 – Waivers of *In Vivo* Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles. [LINK](#)

Human Food Safety

GFI #3 General Principles for Evaluating the Safety of Compounds Used in Food Producing Animals [LINK](#)

GFI # 152 – Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern. [LINK](#)

GFI #159 VICH GL36 - Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI. [LINK](#)

GFI #207 VICH GL48 - Marker Residue Depletion Studies to Establish Product Withdrawal Periods [LINK](#)

GFI # 120 Veterinary Feed Directive Regulation Questions and Answers (Revised) [LINK](#)

Minor Use Minor Species (MUMS)

GFI # 61 – Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species [LINK](#)

GFI # 261- Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs [LINK](#)

New Animal Drug Applications

GFI #132: Administrative Applications and the Phased review Process [LINK](#)

Target Animal: Effectiveness

GFI #56: Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials [LINK](#)

Target Animal : Safety

GFI #56: Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials [LINK](#)

GFI #185 VICH GL43 - Target Animal Safety for Veterinary Pharmaceutical Products [LINK](#)

VICH

GFI #85 VICH GL 9: Good Clinical Practice [LINK](#)

GFI #89 VICH GL 6: Environmental Impact assessments (EIA's) for veterinary Medicinal Products - Phase I [LINK](#)

GFI #166 VICH GL 38: Environmental Impact Assessments (EIA's_ for Veterinary medicinal Products (VMP's) – Phase II [LINK](#)

GFI: E10 Choice of Control Groups and Related Issues in Clinical Trials [LINK](#)

GFI: E9 Statistical Principles for Clinical Trials [LINK](#)

B. Compliance Policy Guidelines Chapter 6- Veterinary Medicine

Links to the following CPGs can be found at [LINK](#)

- [CPG Sec 615.115 Extra-Label Use of Medicated Feeds for Minor Species](#)
- [CPG Sec. 625.200 Availability of Bulk Chemicals for Animal Drug Use](#)
- [CPG Sec. 645.100 Biological Drugs for Animal Use](#)
- [CPG Sec. 650.100 Animal Drugs for Euthanasia](#)
- [CPG Sec. 655.100 Devices for Use in Animals](#)

C. Additional Regulations

Good Laboratory Practice 21 CFR Part 58 [LINK](#)

21 CFR Part 510: New Animal Drugs [LINK](#)

21 CFR Part 511: New Animal Drugs for Investigational Use [LINK](#)

21 CFR Part 514: New Animal Drug Applications [LINK](#)

21 CFR Part 516: New Animal Drugs for Minor Use and Minor Species [LINK](#)

21 CFR Part 530 Extralabel Drug Use in Animals [LINK](#)

21 CFR Part 201 Drug Labeling [LINK](#)

The Animal Medicinal Drug Use Clarification Act (AMDUCA; CFR Title 21) [LINK](#)

Animal Drug Availability Act of 1996 [LINK](#)

Generic Animal Drug and Patent Term Restoration Act (GADPTRA) [LINK](#)

Extralabel Drug Use, including Compounding [LINK](#)

GFI #256 Compounding Animal Drugs from Bulk Drug Substances [LINK](#)

Drugs Prohibited for Use in Food animals [LINK](#)

D. Other Regulatory Sources of Information

Drug Labels

Drug labels provide information on dosage and administration, warnings, contraindications, pharmacokinetic/pharmacodynamic data, safety and effectiveness data, and withdrawal times for food animal drugs.

Freedom of Information Summaries

Each approved veterinary drug has a Freedom of Information (FOI) summary that lists the safety and effectiveness submitted by the drug sponsor to FDA to support the approval of a New Animal Drug Application (NADA) or an Abbreviated New Animal Drug Application (ANADA). The FOI is a public document that provides details on the following studies for each drug approval: dosage characterization, safety, effectiveness studies, and human food safety and environmental (food animals). [LINK](#)

Individual FOIs can be found by drug at [animal drugs @ FDA](#) or by NADA number at [LINK](#).

Recent Animal Drug Approvals [LINK](#)